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The effect of exercise on 
intramyocellular acetylcarnitine 
(AcCtn) concentration in adult 
growth hormone deficiency (GHD)
Fabian Meienberg1, Hannah Loher2, Julie Bucher3, Stefan Jenni4, Marion Krüsi5, Roland Kreis  6, 
Chris Boesch  6, Matthias Johannes Betz  7 & Emanuel christ7*
To cover increasing energy demands during exercise, tricarboxylic cycle (TCA) flux in skeletal muscle is 
markedly increased, resulting in the increased formation of intramyocellular acetylcarnitine (AcCtn). We 
hypothesized that reduced substrate availability within the exercising muscle, reflected by a diminished 
increase of intramyocellular AcCtn concentration during exercise, might be an underlying mechanism 
for the impaired exercise performance observed in adult patients with growth hormone deficiency 
(GHD). We aimed at assessing the effect of 2 hours of moderately intense exercise on intramyocellular 
AcCtn concentrations, measured by proton magnetic resonance spectroscopy (1H-MRS), in seven 
adults with GHD compared to seven matched control subjects (CS). Compared to baseline levels 
AcCtn concentrations significantly increased after 2 hours of exercise, and significantly decreased 
over the following 24 hours (ANOVA p for effect of time = 0.0023 for all study participants; p = 0.067 
for GHD only, p = 0.045 for CS only). AcCtn concentrations at baseline, as well as changes in AcCtn 
concentrations over time were similar between GHD patients and CS (ANOVA p for group effect = 0.45). 
There was no interaction between group and time (p = 0.53). Our study suggests that during moderately 
intense exercise the availability of energy substrate within the exercising muscle is not significantly 
different in GHD patients compared to CS.
Adult growth hormone deficiency (GHD) is characterized by impaired exercise performance. The aerobic capac-
ity (VO2 max) in adults with GHD is reduced by 17% to 27% compared to values predicted for age, gender and 
height1, and there is strong evidence that growth hormone (GH) replacement improves exercise performance in 
GHD patients2. Several potential mechanisms have been postulated to explain this finding3: e.g. anabolic effects of 
GH on skeletal muscle and effects on the cardiovascular system by increasing preload4 and decreasing afterload5 
as well as increasing red cell mass4. Furthermore, and as explained in more detail below, reduced availability of 
energy substrate (in particular free fatty acids (FFA)) within the exercising muscle may play an important role3.
Skeletal muscle contraction and relaxation depend upon energy derived from adenosine triphosphate (ATP). 
With prolonged exercise intracellular energy stores in skeletal muscle (i.e. glycogen and intramyocellular lipids 
(IMCL)) decrease, and ATP production increasingly depends on the supply of glucose and FFA from the systemic 
circulation6 (Fig. 1). These systemic metabolic adaptations are regulated by hormones such as cortisol, catecho-
lamines and growth hormone (GH)7. In the fasting state GH is known as a potent lipolytic hormone, stimulating 
the release and oxidation of FFA from adipose tissue8. The lipolytic effect of GH has been confirmed in studies 
with GHD patients, demonstrating that GH replacement therapy increases lipolysis and tissue uptake of FFA9,10, 
as well as fat oxidation11 during exercise. However, these studies used stable isotope technique to study FFA flux, 
and this method does not provide information on the specific site of FFA uptake. Thus, it remains unproven 
whether these findings really translate into reduced substrate availability within exercising skeletal muscle, and 
possibly thereby limiting exercise performance.
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In contrast to isotope studies, the measurement of skeletal muscle acetylcarnitine (AcCtn) concentrations 
by proton MR spectroscopy (1H-MRS) provides information on energy metabolism specifically from within the 
exercising muscle, and due to its non-invasive nature, this procedure widely obviates the need for repeated muscle 
biopsies.
The formation of skeletal muscle AcCtn serves as a marker for intramuscular ATP production via oxidative 
phosphorylation. In exercising skeletal muscle, changes in AcCtn concentrations are directly related to changes in 
acetyl-CoA (AcCoA) concentrations12–14. AcCoA results from glycolysis and from beta-oxidation of FFA. It enters 
the tricarboxylic acid (TCA) cycle (also known as ‘citric acid cycle’ or ‘Krebs cycle’), which provides the substrates 
for ATP production via oxidative phosphorylation15 (Fig. 1). During exercise - with the increasing demand for 
ATP production - TCA cycle flux in skeletal muscle is dramatically increased (up to 100-fold). This process is 
associated with increased concentrations of various TCA cycle intermediates, including AcCoA16,17. Finally, the 
concentration of AcCoA exceeds the capacity of flow into the TCA cycle13,18. To avoid accumulation of AcCoA 
and thus depletion of free CoA, acetyl groups are transferred from AcCoA to free carnitine, forming AcCtn in a 
reversible reaction19. Hence, free carnitine acts like a sink for excess AcCoA (Fig. 1), and the increase in AcCtn 
concentration reflects the formation of AcCoA.
The missing lipolytic action of GH in adult GHD may be associated with impaired availability of intramus-
cular energy substrate (in particular FFA) during prolonged aerobic exercise. This would result in reduced intra-
muscular beta-oxidation of FFA, and thus reduced formation of AcCoA. Finally, this would result in a blunted 
increase of intramyocellular AcCtn concentration during exercise.
We, therefore, hypothesize that (1) intramyocellular AcCtn levels increase during aerobic physical exercise 
and decrease thereafter. We expect that (2) intramyocellular AcCtn levels increase less in GHD patients compared 
to control subjects (CS).
Methods
We performed a prospective single-center trial at the University Hospital of Bern, Switzerland. The trial was 
approved by the local review board (Ethics Commission of the Canton of Bern, Switzerland) and all subjects 
gave written informed consent. The study was conducted according to the declaration of Helsinki, the guidelines 
of good clinical practice and Swiss health laws on clinical research. This trial was registered under the following 
clinical trial number: NCT01467193.
Study participants. The current paper presents additionally available data of our previous report20; and we 
did not perform a specific power calculation for the main endpoint reported in the present paper.
Briefly, seven male patients with severe GHD and seven male sedentary CS matched for age, BMI and waist 
circumference were included. Severe GHD was defined according to the current guidelines21. All of our partici-
pants were non-institutionalized, in good general health, and capable to exercise on a bicycle ergometer for two 
hours. GHD patients were included if they had been under stable conventional hormone replacement therapy - 
except for GH - as needed (i.e. glucocorticoids, thyroxin and testosterone) for at least 6 months. Inclusion criteria 
for CS were no regular physical activity (<60 minutes/week), and no regular medication intake, as reported in a 
health questionnaire.
Exclusion criteria were (former or present) ACTH- or GH-secreting pituitary adenoma, severe cardiovascular 
disease, diabetes mellitus, abnormal liver or renal function, active neoplasia, hemophilia, and therapy with drugs 
known to affect lipid or glucose metabolism or inability to exercise.
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Figure 1. Formation of acetylcarnitine (AcCtn) and energy supply in the exercising skeletal muscle. During 
exercise, glycolysis and beta-oxidation are markedly increased, and the production of acetyl-Coenzyme A 
(AcCoA) exceeds its entry into the tricarboxylic acid (TCA) cycle. To avoid accumulation of AcCoA, acetyl 
groups are transferred to free carnitine (Ctn) forming Acetylcarnitine (AcCtn). Thus, the increase in AcCtn 
production is directly related to the formation of AcCoA. With prolonged exercise intracellular energy stores 
decrease, and ATP production increasingly depends on the supply of glucose and free fatty acids (FFA) from the 
systemic circulation.
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Study protocol. All the participants attended the research unit for three visits. The first and second visit were 
scheduled within 7–10 days. The third visit was scheduled on the day following the second visit.
Determination of baseline characteristics and VO2max (visit 1). Participants attended the endocrine inves-
tigation unit after an overnight fast and having restrained from physical activity for 72 hours before the test. 
End-expiratory waist circumference was measured with a measuring tape placed on a horizontal plane at the 
level of the iliac crest. A blood sample was taken by venipuncture (Insulin, Glucose, Free fatty acids (FFA), total 
Cholesterol, LDL-Cholesterol, HDL-Cholesterol, Triglycerides, Thyroidea-stimulating-hormone (TSH), free 
Thyroxin (fT4), free Triiodothyronine (fT3), total Testosterone, Follicle-stimulating hormone (FSH), Luteinizing 
hormone (LH), Cortisol, Insulin-like growth factor 1 (IGF-1). Maximal aerobic exercise capacity was determined 
during an incremental workload test on a bicycle ergometer as previously reported22.
Two-hour physical exercise on a bicycle at 50% of VO2max (visit 2 + 3). GHD patients and CS attended the hospital 
after an overnight fast. In the morning, they received a standardized light meal (380 kcal) consisting of 2 deciliter 
of orange juice, yoghurt, curd and cereals. Subsequently, between 1:30 pm and 3:30 pm, patients and CS exercised 
on a bicycle for 2 hours at 50% of the pre-assessed VO2max. This protocol has been shown to reliably deplete IMCL 
stores, and to increase systemic FFA concentrations, indicating systemic lipolysis22,23. In the GHD patients hydro-
cortisone replacement therapy was administered as needed 30 minutes before physical exercise.
Skeletal muscle AcCtn concentrations were measured by 1H-MRS before (0 h, Baseline) and immediately after 
exercise (2 h). Visceral (VAT) and subcutaneous (SCAT) adipose tissue were separately assessed before the exer-
cise using MR images (see below). During the exercise, blood samples were taken from an indwelling catheter.
In the evening after the exercise, the subjects had a standardized meal consisting of 2 deciliter of orange juice, 
yoghurt, curd and cereals. The following morning, subjects received a standardized breakfast (identical amount 
of calories and content as on the day before).
After re-attending the research unit, another blood sample was taken and 24 hours after the exercise a third 
measurement of skeletal muscle AcCtn concentrations was performed (24 h).
Biochemical analysis. Serum IGF-1 concentrations were determined using a chemiluminescent immuno-
metric assay (Immulite, Siemens, Zürich, Switzerland). Cortisol concentrations were measured with Modular 
(Roche, Rotkreuz, Switzerland). Total testosterone concentrations were analyzed using Beckman Coulter RIA 
(IM1119). Plasma glucose concentration levels were measured by an enzymatic hexokinase method (Modular 
P800, Roche). Insulin concentrations were measured with an immunoassay (Architect, Abbott, Baar Switzerland). 
Insulin sensitivity was estimated using homeostasis model assessment (HOMA, glucose × insulin/22.5)24. FFA 
concentrations were determined using a commercially available kit (Wako Chemicals, Dietikon Switzerland). 
Isolation of lipoprotein subfractions, including VLDL and measurements of VLDL-TG were performed as pre-
viously described25.
MR measurements. All magnetic resonance examinations were performed on a Siemens Verio 3 T MR 
system as previously described22.
Skeletal muscle AcCtn concentration. For 1H-MRS of skeletal muscle, the body transmit coil and a local surface 
receive coil array were used in combination with the manufacturer’s standard PRESS sequence (echo time TE 
30 ms, repetition time TR 3 s) to record the signal from the region of interest (ROI, 9 × 9 × 18 mm3) in vastus 
intermedius (prescribed on axial spin echo MR images for repositioning after exercise based on anatomical mark-
ers). A spectrum with water presaturation (50 Hz bandwidth), 96 averages and the transmit frequency centred at 
1.5 ppm was acquired. For quantification and eddy current correction a fully relaxed spectrum of water was also 
recorded (no water suppression, one acquisition, centred at 4.7 ppm, 76% assumed water content for quantifica-
tion). Fitting of the metabolite and IMCL resonances was performed in FiTAID26 using linear combination model 
fitting for the metabolites creatine (Crtot, creatine plus phosphocreatine), trimethyl ammonium compounds 
(TMA), taurine, AcCtn, IMCL and extramyocellular lipids (EMCL). Prior knowledge was used to stabilize the 
fit, in particular of AcCtn superimposed on broader peaks of EMCL and IMCL (fixed frequency differences 
between resonances of Crtot, TMA, taurine and AcCtn). Further constraints for signal modeling included: uni-
form phase, fixed Lorentz widths and a Gaussian width that was allowed to vary per spectrum to adapt to specific 
line broadenings. Furthermore, the dipolar peak patterns of taurine and Crtot were adapted per subject and then 
kept constant for all three spectra recorded. The subpatterns of the lipid spectra were adapted on summed spectra 
and then kept constant for individual fits.
Repositioning of the ROIs in follow-up examinations was based on two steps. Coarse repositioning was 
achieved by placing the leg at the same position relative to the coil using the palpated inferior end of the patella. 
Careful comparison with MR images from the first exam provided guidance for fine repositioning based on visi-
ble fasciae that were carefully evaded in the first examination as well as blood vessels.
SCAT and VAT. SCAT and VAT were assessed as previously described23 using T1-weighted MR images and a 
point-counting method27. Fat compartments were assessed for volume, and then converted to mass (kilograms). 
Lean body mass was calculated by difference.
Statistical analysis. Data are expressed as mean ± standard deviation (SD). Baseline parameters and AcCtn 
concentrations of GHD patients and CS at baseline were compared using the unpaired t-test. Changes in AcCtn 
concentrations between different time points were analyzed by repeated measures ANOVA followed by Sidak’s 
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test for multiple comparisons. Associations between changes in AcCtn concentrations and various parameters 
were analyzed by Pearson correlation.
All statistical analyses were performed with GraphPad Prism Version 8.2 (GraphPad Inc., La Jolla, CA). A 
p-value of < 0.05 was considered statistically significant.
Results
Participants’ clinical and biochemical baseline characteristics. Seven male subjects, aged 26 to 58 
years, with severe GHD and seven sedentary CS a priori matched for age, BMI and waist circumference were 
included in the study.
The characteristics of the GHD subjects, including causes of GHD, treatment of the underlying disease, and 
necessity of hormone replacements are summarized in Table 1. Substitution of corticotropic, gonadotropic and 
thyreotropic axis was established in 4, 6, and 5 patients, respectively. The clinical and biochemical characteristics 
of all participants are summarized in Table 2. Patients and CS were statistically not different with regard to the 
matching criteria, i.e. age, BMI, and waist circumference. Mean BMI was 26.7 kg/m2 (range 20.2–31.8 kg/m2) and 
27.0 kg/m2 (range 23.3–35.2) in GHD patients and CS, respectively. Visceral and subcutaneous fat mass were sim-
ilar in the two groups, as were parameters for lipid and glucose metabolism, cortisol and testosterone levels. As 
expected, IGF-1 levels and VO2max were significantly lower in the GHD patients compared to the CS. Individual 
baseline data are presented in Supplementary Table 1.
Age Diagnosis Treatment Duration of hypopit. (years)
Hormone deficiencies
GH ACTH FSH/LH TSH ADH
26 Medulloblastoma RT 10 x x
37 Pituicytoma Surgery, RT 3 x x x x x
47 NFPA Surgery, RT 8 x x
48 Rathke-Cleft-Cyst Surgery 18 x x x x x
56 Idiopathic Hypopit. — 46 x x
56 NFPA Surgery, RT 21 x x x x
58 Plasmacytoma RT 15 x x x x
Table 1. Clinical characteristics of the seven study participants with growth hormone deficiency (GHD). 
hypopit. = hypopituitarism; NFPA = non-functioning pituitary adenoma; RT = radiotherapy. GH = growth 
hormone; ADH = antidiuretic hormone.
GHD (n = 7) CS (n = 7) p-values
Age (years) 46.9 ( ± 11.7) 39 ( ± 12.6) 0.25
Weight (kg) 80.9 ( ± 15.3) 83 ( ± 14.5) 0.80
LBM (kg) 64.6 ( ± 11.3) 64.8 ( ± 9.4) 0.97
BMI (kg/m2) 26.7 ( ± 3.8) 27.0 ( ± 4.1) 0.88
Waist (cm) 93.3 ( ± 12.8) 91.3 ( ± 13.8) 0.78
Body fat
SAT (kg) 13.8 ( ± 4.3) 13.5 ( ± 5.9) 0.91
VAT (kg) 3.5 ( ± 1.5) 2.2 ( ± 1.8) 0.22
Exercise capacity
VO2max (ml*kg−1 min−1) 30.5 ( ± 6.2) 42.8 ( ± 10.9) 0.03
Fasting biochemical parameters
Glucose (mmol/L) 4.9 ( ± 0.4) 5.4 ( ± 1.0) 0.19
Total Cholesterol (mmol/L) 5.4 ( ± 1.1) 5.8 ( ± 1.0) 0.46
HOMA 2.4 ( ± 1.5) 2.8 ( ± 2.3) 0.70
LDL-Cholesterol (mmol/L) 3.7 ( ± 1.1) 3.9 ( ± 0.8) 0.72
Triacylglycerol (mmol/L) 1.4 ( ± 0.7) 1.3 ( ± 1.0) 0.84
VLDL-TG (mmol/L) 0.83 ( ± 0.70) 0.76 ( ± 0.75) 0.85
FFA (mmol/L) 0.5 ( ± 0.1) 0.7 ( ± 0.4) 0.20
Cortisol (nmol/L) 468.7 ( ± 172.5) 433.3 ( ± 113.9) 0.68
IGF-1 (ng/ml) 80.2 ( ± 47.5) 139.5 ( ± 33.2) 0.02
Testosteron (nmol/L) 22.6 ( ± 11.4) 17.7 ( ± 4.8) 0.31
Table 2. Clinical and biochemical characteristics fat mass and exercise capacity of the GHD patients and CS 
participating in the study. GHD = patients with growth hormone deficiency; CS = control subjects. waist = waist 
circumference; LBM = lean body mass; SAT = subcutaneous adipose tissue mass; VAT = visceral adipose tissue 
mass; VO2max = maximal oxygen uptake; HOMA = HOMA-Index: fasting Insulin*fasting Glucose*22,5−1; 
FFA = free fatty acids. Values are mean ( ± SD), bold p-values: statistically significant (p < 0.05).
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Skeletal muscle AcCtn concentrations. Representative spectra obtained from a control subject at all 
three time points are presented in Fig. 2. Intramyocellular AcCtn concentrations at baseline and changes over 
time are shown in Table 3. With regard to the entire study population (n = 14, GHD and CS taken together) base-
line levels of AcCtn concentrations significantly increased after 2 hours of exercise, and significantly decreased 
over the following 24 hours (ANOVA p for effect of time = 0.0023). The same effect has been observed within each 
of the two groups (GHD and CS), although the effect did only reach borderline significance (ANOVA p = 0.067 in 
GHD, p = 0.045 in CS). AcCtn concentrations at baseline (p = 0.90), as well as changes in AcCtn concentrations 
over time were similar between GHD patients and CS (ANOVA p for group effect = 0.45). There was no interac-
tion between group and time (p = 0.53).
Individual AcCtn concentrations over time in GHD patients and CS are shown in Fig. 3. Individual outcome 
data are presented in Supplementary Table 1. As there was considerable individual variation in the change of 
AcCtn concentrations over time, we repeated the ANOVA after exclusion of participants who did not show the 
expected increase of AcCtn with exercise (GHD participants 2 + 5, CS participant 5; Supplementary Table 1). As 
expected, the effect of time became more significant (p = 0.0007), whilst there was still no significant effect with 
respect to group (p = 0.53).
With regard to the entire study population (n = 14) changes in AcCtn concentrations over time did not corre-
late with the following baseline parameters: age, BMI, VO2max, HOMA index, lean body mass, total fat mass, VAT, 
SCAT (Supplementary Table 2).
Discussion
The main findings of the current study can be summarized as follows: (1) two hours of moderately intense exer-
cise result in a transitory increase in skeletal muscle AcCtn and a decrease 24 h thereafter, and (2) GHD does not 
significantly affect changes in skeletal muscle AcCtn during and after exercise.
The current finding of an increase of AcCtn after a 2 h moderate intensity aerobic exercise is consistent with 
previous studies that assessed AcCtn using repetitive skeletal muscle biopsies14,19,28. Importantly, studies using the 
non-invasive tool, namely 1H-MRS, confirmed the exercise-induced increase in AcCtn during short-term, high 
intensity29–32 and prolonged, moderately intense exercise30,33,34. This indicates that 1H-MRS is a reliable tool to 
assess changes in intramyocellular AcCtn concentration during exercise.
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Figure 2. Representative spectra of a control subject. The AcCtn peak, i.e. the resonance of the acetyl group of 
the molecule that is visible as a singlet at 2.1 ppm, documents clearly elevated tissue content 2 hours after aerobic 
exercise, and decreases over the following 24 hours. Spectral quality and its reproducibility is excellent, as 
readily documented by equal EMCL contributions (identical region of interest) and identical peak splitting for 
the Cr2 peak (identical muscle fiber orientation in the magnet) at all three time points. AcCtn = acetylcarnitine; 
IMCL = intramyocellular lipids; EMCL = extramyocellular lipids; TMA = trimethyl ammonium compounds; 
Cr2, Cr3 = Creatine.
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Our data demonstrate that 24 hours after exercise, intramuscular AcCtn returned towards baseline levels. To 
our knowledge, these measurements are a new finding indicating that the availability of AcCtn is – like intramy-
ocellular lipids – flexible with a consistent increase immediately after exercise and a decrease thereafter. It has 
previously been shown that 10–15 minutes after the cessation of short-term high intensity exercise AcCtn levels 
start to decrease but remain elevated compared to pre-exercise values13,29. It is conceivable that differences in 
exercise protocol (high-intensity vs moderate intensity) and time point of measurement of intramuscular AcCtn 
influence the results.
Our study has demonstrated that with the exercise protocol applied, GHD does not significantly impact on 
changes in skeletal muscle AcCtn, and thus the formation of AcCoA. As we did not measure exhaled air during 
the exercise (to determine the respiratory exchange ratio), we cannot determine whether the source of AcCoA 
(glycolysis vs. beta-oxidation of FFAs) differed between GHD patients and CS. However, overall mitochondrial 
ATP production does not seem to be impaired in GHD patients. As expected, GH concentrations did not increase 
during exercise in GHD patients, suggesting reduced GH-induced systemic lipolysis. However, the systemic avail-
ability of FFA (expressed as AUC of FFA) was similar in GHD patients and CS, only peak serum FFA concentra-
tions at the end of physical exercise were lower in GHD patients compared to CS (full data shown in our previous 
report20). This suggests that there are redundant endocrine systems affecting lipolysis (catecholamines, cortisol) 
which are sufficient to guarantee an adequate energy supply during moderate intensity exercise. In contrast, in 
another study assessment of systemic lipolysis using stable isotope technique indicated that lipolysis during exer-
cise is reduced in GHD patients9. However, in this study a very different exercise protocol (15–30 min exercise 
until exhaustion) has been applied, which may explain the dissimilar results. Taken together, impaired exercise 
capacity seen in GHD patients is rather not related to significantly impaired lipolysis, during moderate intensity 
exercise.
The strength of our study lies in the a priori matching of CS for age, BMI, and waist circumference as part of 
the study design. Importantly, the matching for waist circumference, resulting in similar amounts of SCAT and 
VAT, did allow us to specifically examine short-term metabolic adaptions to exercise in GHD - independently of 
the characteristically increased fat mass observed in these patients. In addition, insulin concentrations and insulin 
sensitivity - important regulatory factors of lipolysis35 - were not statistically different between GHD patients and 
CS. The strict standardization of diet and exercise during the study (as potential factors influencing metabolism 
in the exercising muscle) is a further, essential strength of our study.
all study participants (n = 14) GHD (n = 7) CS (n = 7)
Baseline 0.35 ( ± 0.48) 0.33 ( ± 0.50) 0.38 ( ± 0.51)
2 hours 1.66 ( ± 1.47) 1.30 ( ± 1.19) 2.01 ( ± 1.72)
24 hours 0.75 ( ± 0.78) 0.63 ( ± 0.43) 0.88 ( ± 1.05)
p-value (time course) (ANOVA) p = 0.0023 p = 0.067 p = 0.045
p-value for group effect (ANOVA) P = 0.45 No significant interaction between group and time
Table 3. Intramyocellular acetylcarnitine (AcCtn) concentrations (mmol/kg) at baseline, after 2 hours of 
exercise, and 24 hours post-exercise. GHD = patients with growth hormone deficiency; CS = control subjects. 
Values are mean ( ± SD). Differences between time-points were tested after repeated measures ANOVA by 
Sidak’s multiple comparison test versus baseline. AcCtn concentrations at baseline (unpaired t-test, p = 0.90), as 
well as changes over time (ANOVA) were similar between GHD and CS.
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Figure 3. Changes in intramyocellular acetylcarnitine (AcCtn) concentrations of seven patients with GHD 
(right) and seven CS (left). Intramyocellular AcCtn concentrations were measured by proton magnetic 
resonance spectroscopy (1H-MRS) at baseline (0 h), 2 hours after moderately intense exercise (2 h), and 24 hours 
post-exercise (24 h). Changes of AcCtn concentrations over time did not significantly differ between GHD 
patients and CS (ANOVA p for group = 0.45). Bars, boxes and whiskers represent median, IQR and range. 
GHD = growth hormone deficiency, CS = control subjects.
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Still, there are several limitations in this study: (1) we included only male GHD patients and CS in order to 
avoid possible sex hormone induced heterogeneity in lipid metabolism. (2) It is possible that due to the small 
number of participants included, subtle differences between GHD patients and CS may have escaped detection, 
as suggested by the fact that numerically the increase in AcCtn with exercise was more pronounced in CS than 
in GHD patients. This restriction was mainly due to the sophisticated and time-consuming investigations and 
the strict matching criteria of CS with the patients with GHD. (3) AcCtn levels were measured immediately after 
and, strictly speaking, not during exercise. Differences in the dynamics of declining AcCtn levels after exercise 
could have blunted an inherent difference of AcCtn levels during exercise. However, as our protocol consisted of 
steady-state exercise we assume that post-exercise AcCtn concentrations provide a reasonable indicator of sub-
strate availability during exercise.
In conclusion, based on measurements of AcCtn concentrations, our study suggests that during exercise the 
availability of energy substrate within the exercising muscle is not significantly different in GHD patients com-
pared to CS. The redundant metabolic actions of other hormones (catecholamines, cortisol) probably compensate 
for the reduced lipolytic activity in GHD. The known effects of GH on skeletal muscle and on the cardiovascular 
system appear to be more important to improve the impaired exercise capacity than GH-induced metabolic 
effects on energy substrate availability.
Data availability
The datasets generated or analyzed during the current study are available from the corresponding author on 
reasonable request.
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